Financial Performance - The company's operating revenue for 2023 was CNY 207.38 million, a decrease of 11.16% compared to the previous year[4] - Net profit attributable to shareholders was CNY 23.74 million, down 15.93% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 21.44 million, a decline of 14.89% from the previous year[4] - Basic earnings per share decreased to CNY 0.38, down 19.15% compared to the same period last year[4] Assets and Equity - Total assets at the end of the reporting period were CNY 412.29 million, an increase of 6.34% year-on-year[5] - Shareholders' equity attributable to the company increased to CNY 333.77 million, up 16.34% from the beginning of the period[5] - The increase in shareholders' equity and share capital was mainly due to the public issuance of shares to unspecified qualified investors[6] Revenue Decline Factors - The decrease in operating revenue was primarily due to a decline in sales from medical device-related products, which fell by CNY 24.06 million[6] - The increase in expenses related to stock-based compensation and higher R&D investment in new products contributed to the decline in net profit[6] Cautionary Note - The company warns that the financial data presented is preliminary and has not been audited, urging investors to be cautious[7]
阿为特(873693) - 2023 Q4 - 年度业绩